SEARCH:   Advanced

Blood, 1 May 2007, Vol. 109, No. 9, pp. 3672-3675. Prepublished online as a Blood First Edition Paper on January 5, 2007; DOI 10.1182/blood-2006-08-042929. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2006-08-042929v1 109/9/3672    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Robak, T. Articles by Konopka, L. Search for Related Content PubMed PubMed Citation Articles by Robak, T. Articles by Konopka, L. Related Collections Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Brief Report Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial Tadeusz Robak1, Krzysztof Jamroziak1, Joanna Gora-Tybor1, Jerzy Z. Blonski1, Marek Kasznicki1, Jadwiga Dwilewicz-Trojaczek2, Elzbieta Wiater2, Andrzej Zdunczyk3, Jacek Dybowicz3, Anna Dmoszynska4, Maria Wojtaszko4, Barbara Zdziarska5, Malgorzata Calbecka6, Aleksandra Kostyra6, Andrzej Hellmann7, Krzysztof Lewandowski7, Beata Stella-Holowiecka8, Kazimierz Sulek9, Krzysztof Gawronski9, Aleksander B. Skotnicki10, Wieslaw Nowak10, Krystyna Zawilska11, Lucyna Molendowicz-Portala11, Janusz Kloczko12, Jarosaw Sokolowski12, Krzysztof Warzocha13, Ilona Seferyska13, Bernardeta Ceglarek13, Lech Konopka13, for the Polish Adult Leukemia Group 1 Department of Hematology, Medical University of Lodz; 2 Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw; 3 Department of Hematology, City Hospital, Krakow; 4 Department of Hematology and Bone Marrow Transplantation, Medical University of Lublin; 5 Department of Hematology, Pomeranian Medical University, Szczecin; 6 Department of Hematology, City Hospital, Torun; 7 Department of Hematology, Medical University of Gdansk; 8 Department of Hematology and Bone Marrow Transplantation, Medical University, Katowice; 9 Department of Internal Medicine, Military Institute of Medicine, Warsaw; 10 Department of Hematology, Jagiellonian University, Krakow; 11 Department of Hematology, Medical University of Poznan; 12 Department of Hematology, Medical University of Bialystok; 13 Institute of Hematology and Transfusiology, Warsaw, Poland Cladribine (2-chlorodeoxyadenosine, 2-CdA) treatment-associated infections may shorten potentially long-term survival in hairy cell leukemia (HCL). In search of the optimal mode of 2-CdA administration, 132 patients with untreated HCL were randomized to receive either standard 5-day 2-CdA protocol or a novel schedule of 6 weekly 2-CdA infusions suggested to be less toxic. Analysis of treatment response confirmed similar complete remission rates, overall response rates, progression-free survival, and overall survival in both 2-CdA protocols. However, we did not observe lower toxicity in the weekly schedule. Of special interest, no significant differences were found in the rate of grade 3/4 infections (18% for daily and 26% for weekly protocol, difference –8.2%; 95% confidence interval [CI] –23.2% to 6.9%; P = .28) and the rate of septic deaths (3% for daily and 2% for weekly protocol, difference 1.4%; 95% CI –4.3% to 7.0%; P = .64). In conclusion, HCL treatment with weekly 2-CdA infusions is equally effective but no safer than the standard 5-day 2-CdA protocol. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: Cladribine Therapy for Hairy Cell Leukemia: Does Schedule Matter? Journal Watch Oncology and Hematology, May 25, 2007; 2007(525): 1 - 1. [Full Text]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020